Parent stress and treatment follow-through in childhood brain tumor
Part of Cancer clinical trials.
This study looks at how stress affects parents who care for children with medulloblastoma that has come back. By asking parents to fill out questionnaires, the researchers want to understand what makes it harder or easier to follow treatment plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has medulloblastoma that has come back after previous treatment
- Your child is 18 years old or younger and is currently being treated for the recurrence
- Your child is expected to live at least 3 more months
- You are the main parent or guardian who gives the medicines and coordinates the child's care
- You are 18 years or older and can read and understand English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard treatments for a type of brain tumor called SHH-activated medulloblastoma in children under 5. The goal is to see which treatment better protects thinking and learning skills over time.
This study looks at the long-term health of people who were treated for medulloblastoma with craniospinal radiation at St. Jude Children's Research Hospital. It aims to understand how they are doing years after treatment.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial studies how brain tumors (like high-risk gliomas, medulloblastoma, and ependymoma) respond to treatment and why they sometimes become resistant. It is for young people aged 15 to 39 and aims to use tumor tissue samples to understand the tumor better and guide future therapies.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.